Circulating Neuroendocrine Tumor Gene Signature, the NETest, Defines Therapy in GEP-NETs

#1497

Introduction: Early and precise delineation of therapeutic responses are key issues in GEP-NET management. Imaging has limitations in sensitivity while secretory biomarkers e.g., CgA is controversial.

Aim(s): Evaluate whether NETest predicts responses to somatostatin analogs (SSAs) in a prospective clinical trial.

Materials and methods: Test set: n=35 SSA-treated (RECIST-evaluated) to establish cut-offs to differentiate stable from progressive disease. Prospective trial set: n=28 SSA-treated Grade 1 (n=12)/Grade 2 (n=16) GEP-NETs. CgA (ELISA, normal <109ng/ml) and NETest (qRT-PCR with multianalyte algorithmic analyses: scale, 0–100%). Blood was evaluated monthly prior to SSA injection. CT/MRI were undertaken at entry and 6 monthly until progression (RECIST 1.0).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Kolasinska-Cwikla A

Authors: Kolasińska-Ćwikła A, Cwikła J, Bodei L, Sankowski A, Drozdov I,

Keywords: NETest, CgA, PCR,